By Kathryn Calkins
Staff writer

Axys Pharmaceuticals Inc. is making its move away from dependence on drug discovery partnerships and toward its redefinition as a vertically integrated product company. The company intends to concentrate its internal development on building an oncology franchise, a crowded market where AXPH believes its expertise in proteases as therapeutic targets as well as its chemistry and pharmacology capabilities will enable it to compete.